Alpine Immune Sciences Inc is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins.
| Website: | www.alpineimmunesciences.com |
| Email: | jgraziano@troutgroup.com |
| Main Phone: | +1 206 788-4545 |
| Address: | 201 Elliott Avenue West |
| Address 2: | Suite 230 |
| State: | WA |
| City / Town: | Seattle |
| Country: | USA |
| Postal Code: | 98119 |
| Exchange: | NSD |
| CEO: | Mitchell H. Gold |
| Employees: | 48 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Each year on February 4th, World Cancer Day empowers all of us to show support, raise our collective voice, take personal action and press our governments to do more.
Company recently showed positive data in cancer and graft versus host disease.
ALPN-202 combines dual checkpoint blockade action with T-cell costimulation
Alpine Immune Sciences Inc is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins.
| Website: | www.alpineimmunesciences.com |
| Email: | jgraziano@troutgroup.com |
| Main Phone: | +1 206 788-4545 |
| Address: | 201 Elliott Avenue West |
| Address 2: | Suite 230 |
| State: | WA |
| City / Town: | Seattle |
| Country: | USA |
| Postal Code: | 98119 |
| Exchange: | NSD |
| CEO: | Mitchell H. Gold |
| Employees: | 48 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Each year on February 4th, World Cancer Day empowers all of us to show support, raise our collective voice, take personal action and press our governments to do more.
Company recently showed positive data in cancer and graft versus host disease.
ALPN-202 combines dual checkpoint blockade action with T-cell costimulation
| Last Price 3.15 | Change $ -0.04 | Change % -1.25 | Tick N/A |
| Bid 3.00 | Bid Size 100.00 | Ask 3.19 | Ask Size 100.00 |
| Open 3.06 | High 3.15 | Low 2.96 | Prev Close 3.19 |
| Last Trade | Volume 1,829 | 52 Wk Hi 8.25 | 52 Wk Low 2.25 |
| Market Cap 58.6 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 18,587,768.00 | EPS (TTM) -2.76 | PE Ratio N/A | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 11 |
| Number of Buys | 0 | 11 |
| Number of Sells | 0 | 0 |
| Net Activity | 0 | 13262171 |
| Last 10 Buys | Shares |
|---|---|
| Mark N. Lampert | 1,000 |
| Mark N. Lampert | 1,000 |
| Mark N. Lampert | 1,000 |
| Mark N. Lampert | 1,000 |
| Mark N. Lampert | 1,000 |
| Mark N. Lampert | 1,000 |
| Mark N. Lampert | 1,000 |
| Mark N. Lampert | 1,000 |
| Mark N. Lampert | 1,000 |
| Mark N. Lampert | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| David Rodman | 1,000 |
| David Rodman | 1,000 |
| David Rodman | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 17 | 17 | 17 | 17 |
| Low Target Price Estimate | 13 | 13 | 13 | 13 |
| Mean Target Price Estimate | 15 | 15 | 15 | 15 |
| Standard Deviation | 2.83 | 2.83 | 2.83 | 2.83 |
| Date of Most Recent Estimate | 05/25/18 | 05/25/18 | 05/25/18 | 05/25/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| S-8 | Securities offered to employees under employee benefit plans | 7 | 2018-06-21 |
| 8-K | Report of unscheduled material events or corporate changes. | 36 | 2018-06-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 46 | 2018-06-11 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 93 | 2018-06-11 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 65 | 2018-05-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 7 | 2018-05-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-04-24 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-04-24 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-04-24 |
| DEFA14A | Additional proxy soliciting materials - definitive | 5 | 2018-04-24 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait